Pathogenesis and spectrum of autoimmunity

Methods in Molecular Biology

Volumn 900, Issue , 2012, Pages 1-9

  Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Autoantigens; Autoimmune diseases; Autoimmunity; Biomarkers; Environment; Genetics; Tolerance; Treatment

Indexed keywords

EID: 84868594604     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-720-4_1     Document Type: Article

References (34)

1. Oldstone MBA (1987) Molecular mimicry and autoimmune disease. Cell 50:819-8200
2. Nagata S (2010) Apoptosis and autoimmune diseases. Ann N Y Acad Sci 1209:10-166
3. Waterman PM, Cambier J.C. (2010) The conundrum of inhibitory signaling by ITAMcontaining immunoreceptors: Potential moleular mechanisms. FEBS Lett 584:4878-48822
4. Sakaguchi S (2011) Regulatory T cells: History and perspective. Methods Mol Biol 707:3-177
5. Silverman G.J. (2011) Regulatory natural autoantibodies to apoptotic cells: Pallbearers and protectors. Arthritis Rheum 6:597-6022
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra H.S. (1988) The American Rheumatism Association 1987 revised criteria for the classi fi cation of rheumatoid arthritis. Arthritis Rheum 31:315-3244
7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Roth fi eld NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classi fi cation of systemic lupus erythematosus. Arthritis Rheum 25: 1271-12777
8. Perl A (2010) Systems biology of lupus: Mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity 43:32-477
9. Silverstein AM, Rose NR (1997) On the mystique of the immunological self [review] [91 refs]. Immunol Rev 159:197-206, discussion 10. Agnello V (1986) Lupus diseases associated with hereditary and acquired de fi ciencies of complement. Springer Semin Immunpathol 9:183-2199
10. Arnett FC, Reveille JD (1992) Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 18:865-8922
11. Ehrlich P (1900) On immunity with special reference to cell life. Proc R Soc Lond (Biol) 66:428-4488
12. Rose NR, Witebsky E (1956) Studies on organ speci fi city. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunol 76:417-4277
13. Steinberg AD, Gourley MF, Klinman DM, Tsokos GC, Scott DE, Krieg AM (1991) Systemic lupus erythematosus. Ann Intern Med 115:548-5599
14. Samter M, Talmage DW, Frank MM, Austen KF, Claman HN (1988) Immunological diseases. Little Brown, Boston, MA 16. Brand DD, Kang AH, Rosloniec EF (2004) The mouse model of collagen-induced arthritis. In: Perl A (ed) Autoimmunity: Methods and protocols, 102nd edn. Humana, Totowa, NJ, pp 295-3122
15. Abu-Hamad S, Sivan S, Shoshan-Barmatz V (2006) The expression level of the voltagedependent anion channel controls life and death of the cell. PNAS 103:5787-57922
16. Liu E, Yu L, Moriyama H, Eisenbarth GS (2004) Animal models of insulin-dependent diabetes, 102 edn. In: Perl A (ed) Humana, Totowa, NJ. pp 195-2122
17. Slavin A, Kelly-Modis L, Labadia M, Ryan K, Brown ML (2010) Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity 43:504-5133
18. Mageed RA, Isenberg DA (2002) Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production [review] [45 refs]. Lupus 11:850-8555
19. Wang J, Asensio VC, Campbell IL (2002) Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice. [Review] [146 refs]. Curr Top Microbiol Immunol 265:23-488
20. Ghezzi P, Mennini T (2001) Tumor necrosis factor and motoneuronal degeneration: An open problem [Review] [51 refs]. Neuroimmunomodulation 9:178-1822
21. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935-9466
22. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-16499
23. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ (1999) (1999) Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98:47-588
24. Cohen PL, Eisenberg RA (1991) Lpr and gld : Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-2699
25. Clerici M, Fusi ML, Caputo D, Guerini FR, Trabattoni D, Salvaggio A, Cazzullo CL, Arienti D, Villa ML, Urnovitz HB, Ferrante P (1999) Immune responses to antigens of human endogenous retroviruses in patients with acute or stable multiple sclerosis. J Neuroimmunol 99:173-1822
26. Georgescu L, Vakkalanka RK, Elkon KB, Crow MK (1997) Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 100: 2622-26333
27. Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH, Chibnik LB, Ha fl er DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR (2011) Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med 3:33
28. Steck AK, Rewers MJ (2011) Genetics of type 1 diabetes. Clin Chem 57:176-1855
29. Crow MK, Kirou KA (2004) Interferon-Alpha in systemic lupus erythematosus. [Review] [74refs]. Curr Opin Rheumatol 16:541-5477
30. Perl A (1999) Mechanisms of viral pathogenesis in rheumatic diseases (Invited Review). Ann Rheum Dis 58:454-4611
31. Lai Z-W, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, Miklossy G, Jimah J, Doherty E, Tily H, Francis L, Garcia R, Dawood M, Yu J, Ramos I, Coman I, Faraone SV, Phillips PE, Perl A (2012) N-Acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arth Rheum Accepted Article', DOI 10.1002/art.345022
32. Fernandez D, Bonilla E, Mirza N, Perl A (2006) Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fl uxing in patients with systemic lupus erythematosus. Arthritis Rheum 54:2983-29888
33. Warner LM, Adams LM, Sehgal SN (1994) Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 37: 289-2977
34. Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H, Zhou XJ, Satterthwaite AB, Davis LS, Mohan C (2007) Shared signaling networks active in B cells isolated from geneticallyy